98%
921
2 minutes
20
Background: Iatrogenic atrial septal defects (iASD) are created during transseptal (TS) mitral valve-in-valve (MViV) implantation to facilitate access. Although most iASD remain untreated, the outcomes of closing iASD during TS MViV are unclear. This study evaluates outcomes of concomitant iASD closure during TS MViV.
Methods: Patients undergoing TS MViV with SAPIEN 3/Ultra/Resilia valves from June 2015 to September 2023 were identified using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. To reduce patient selection bias in the primary analysis, MViV patients without iASD closure were chosen from sites that did not perform iASD closures. Propensity score matching accounted for baseline characteristics, and analyses evaluated procedural success, complications, and 1-year clinical outcomes.
Results: Among 5363 TS MViV patients, 472 (8.8%) underwent iASD closure at 173 of 494 sites (35.0%). Propensity matching yielded 468 patient pairs (34% male, 66% female). No significant differences were observed in procedural success, complications, stroke (3.3% vs 5.2%; = .26), or mortality (18.8% vs 17.3%; = .54). Rates of New York Heart Association class III/IV and heart failure rehospitalization were also similar. However, in patients with severe pulmonary hypertension (mean pulmonary artery pressure, 47.4 ± 8.6 mm Hg), iASD closure was associated with higher 30-day mortality (9.7% vs 3.9%; = .03) and 1-year cardiac readmission rates (14.1% vs 4.1%; = .008).
Conclusions: Iatrogenic atrial septal defect closure during the index hospitalization for TS MViV patients is a well-tolerated procedure when performed in carefully selected individuals. However, no significant clinical benefits were observed in the iASD closure group. Additionally, patients with significant pulmonary hypertension did not demonstrate any clinical advantage from iASD closure, and the procedure may even pose potential harm in this subgroup.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230488 | PMC |
http://dx.doi.org/10.1016/j.jscai.2025.102636 | DOI Listing |
J Soc Cardiovasc Angiogr Interv
June 2025
Cardiovascular Surgery, Ascension Saint Thomas Heart West, Nashville, Tennessee.
Background: Iatrogenic atrial septal defects (iASD) are created during transseptal (TS) mitral valve-in-valve (MViV) implantation to facilitate access. Although most iASD remain untreated, the outcomes of closing iASD during TS MViV are unclear. This study evaluates outcomes of concomitant iASD closure during TS MViV.
View Article and Find Full Text PDFClin Med Insights Cardiol
April 2025
Department of Cardiology and Electrotherapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.
Introduction: Iatrogenic atrial septal defect (iASD) resulting from MitraClip procedures may cause volume overload and deterioration of right ventricular (RV) function. The concurrent MitraClip procedure, along with an intervention to close iASD appears to yield a potentially favorable impact on the functioning of the right ventricle.
Aim Of The Study: The study aims to evaluate the effect of iASD closure with an occluder immediately after the MitraClip procedure on RV function, pulmonary resistance, and right ventricle-pulmonary artery coupling (RV-PAc).
Sci Rep
January 2025
Cardiovascular Research Institute, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang, 110016, Liaoning, China.
Using transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) to investigate the occurrence and related causes of iatrogenic atrial septal defect (iASD) after catheter ablation combined with left atrial appendage closure (LAAC) for atrial fibrillation (AF) and its impact on the right heart system. We retrospectively analyzed 330 patients that underwent combined procedure of catheter ablation for AF and LAAC at General Hospital of Northern Theater Command from January 2018 to March 2022. These patients were divided into iASD group and non-iASD group according to whether there was persistent iASD shown on TEE at 3 months after procedure.
View Article and Find Full Text PDFJ Cardiol Cases
November 2024
The Second Department of Internal Medicine, University of Toyama, Toyama, Japan.
Catheter Cardiovasc Interv
November 2024
First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece.
In the modern era of structural heart interventions, the total number of transseptal procedures is growing exponentially, thus increasing the rate and need for management of iatrogenic atrial septal defects (iASDs). To date, there are no official guidelines on the assessment and management of iASDs, due to inconclusive evidence on whether patients benefit more from the percutaneous closure of iASD than from conservative management and vigorous follow-up. Despite the abundance of observational studies on iASDs, there is still a lack of randomized studies.
View Article and Find Full Text PDF